Combined serum eosinophil count and procalcitonin level as a marker of bacterial infection in acute exacerbation of chronic obstructive pulmonary disease Source: International Congress 2016 – Systemic biomarkers Year: 2016
The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014
Clinical value of C-reactive protein in severe acute exacerbations of COPD Source: Annual Congress 2005 - COPD - acute exacerbations Year: 2005
Serum procalcitonin (PCT-Q) as a diagnostic tool for bacterial lower respiratory tract infection among COPD patients with acute exacerbation Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013
Effects of an acute exacerbation requiring hospitalisation (AE) on lung function, muscle force and serum IGF-I levels in male patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 564s Year: 2002
Evaluation of neutrophil lymphocyte ratio and C-reactive protein values in the treatment of acute chronic obstructive pulmonary disease exacerbation according to endotype Source: Virtual Congress 2020 – Monitoring of patients with COPD Year: 2020
Pro-adrenomedullin and pro-endothelin-1 for assessment and prognosis of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) Source: Eur Respir J 2007; 30: Suppl. 51, 39s Year: 2007
C-reactive protein levels and clinically important predictive outcomes in stable COPD patients Source: Eur Respir J 2006; 27: 902-907 Year: 2006
Value of ²GOLD² reversibility test criteria in detecting ²reversible² chronic obstructive pulmonary disease (COPD) patients Source: Eur Respir J 2004; 24: Suppl. 48, 122s Year: 2004
The influence of co-morbidity on the outcome of non-invasive ventilatory support in patients with acute respiratory failure (ARF) in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 277s Year: 2002
Application of an outcome prediction model for hospitalized patients with exacerbation of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 55s Year: 2005
Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD Source: Eur Respir J 2012; 40: 1344-1353 Year: 2012
The importance of C-reactive protein in patients with acute exacerbation of severe COPD Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019
Differential therapy of acute respiratory failure (ARF) in chronic obstructive pulmonary disease (COPD) patients with predominance of emphysema (PE) and predominance of bronchitis (PB) Source: Eur Respir J 2006; 28: Suppl. 50, 395s Year: 2006
Patient’s knowledge about risk factors for acute exacerbation( AE ) of chronic obstructive pulmonary disease( COPD ) Source: Eur Respir J 2004; 24: Suppl. 48, 514s Year: 2004
LATE-BREAKING ABSTRACT: The predictive value of the COPD assessment test (CAT) for acute exacerbations in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2012 - New insights in pneumology - ERS inter-Assemblies late-breaking abstracts Year: 2012
Usefulness of admission red cell distribution Width as a predictor of early mortality in patients with severe exacerbation of chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD biomarkers Year: 2013
C-reactive protein (C-RP) in patients with chronic heart failure (CHF) and community-acquired pneumonia (CAP): usefulness to guide antibiotic prescription Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018
The safety of sputum induction in patients with exacerbation of severe and very severe COPD (chronic obstructive pulmonary disease) Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008
Utility of procalcitonin, neopterin, C-reactive protein and MR-proANP measurement in the management of exacerbations in chronic obstructive pulmonary disease Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008